Germline Findings in Tumor-Only Sequencing: Points to Consider for Clinicians and Laboratories
- PMID: 26590952
- PMCID: PMC4849259
- DOI: 10.1093/jnci/djv351
Germline Findings in Tumor-Only Sequencing: Points to Consider for Clinicians and Laboratories
Abstract
Precision oncology holds great potential to improve patient therapies and outcomes. Tumor sequencing is rapidly moving into clinical care as our understanding of the cancer genome and the availability of targeted therapies increase. Analysis of the cancer genome is most informative when paired with germline genomic DNA to delineate inherited and somatic variants. Although tumor-only analysis remains the most common methodology for numerous reasons, it holds the potential to identify clinically significant germline variants. Here, we provide anticipatory guidance and points to consider for laboratories and clinicians regarding the potential for germline findings in tumor sequencing.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
References
-
- Garraway LA. Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol. 2013;31 (15):1806–1814. - PubMed
-
- Wolff AC, Hammond MEH, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31 (31):3997–4013. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
